Elisabeth J Adams
Overview
Explore the profile of Elisabeth J Adams including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Harding-Esch E, Huntington S, Harvey M, Weston G, Broad C, Adams E, et al.
Euro Surveill
. 2020 Oct;
25(43).
PMID: 33124553
BackgroundWidespread ceftriaxone antimicrobial resistance (AMR) threatens (NG) treatment, with few alternatives available. AMR point-of-care tests (AMR POCT) may enable alternative treatments, including abandoned regimens, sparing ceftriaxone use. We assessed cost-effectiveness...
12.
Fleming C, Drennan V, Kerry-Barnard S, Reid F, Adams E, Sadiq S, et al.
BMC Public Health
. 2020 Aug;
20(1):1212.
PMID: 32770977
Background: Low uptake of sexually transmitted infection testing by sexually active young people is a worldwide public health problem. Screening in non-medical settings has been suggested as a method to...
13.
Weston G, Dombrowski C, Harvey M, Iftner T, Kyrgiou M, Founta C, et al.
BMJ Open
. 2020 Mar;
10(3):e031303.
PMID: 32152154
Objective: To estimate the impact of using the Aptima messenger RNA (mRNA) high-risk human papilloma virus (HR-HPV) assay versus a DNA HR-HPV assay in a primary HPV cervical screening programme....
14.
Huntington S, Burns R, Harding-Esch E, Harvey M, Hill-Tout R, Fuller S, et al.
BMJ Open
. 2018 Sep;
8(9):e020394.
PMID: 30201794
Objectives: To quantify the costs, benefits and cost-effectiveness of three multipathogen point-of-care (POC) testing strategies for detecting common sexually transmitted infections (STIs) compared with standard laboratory testing. Design: Modelling study....
15.
Kerry-Barnard S, Fleming C, Reid F, Phillips R, Drennan V, Adams E, et al.
Trials
. 2018 Jun;
19(1):311.
PMID: 29871673
Background: Sexually active young people attending London further education (FE) colleges have high rates of chlamydia, but screening rates are low. We will conduct a cluster randomised feasibility trial of...
16.
Vecino-Ortiz A, Goldenberg S, Douthwaite S, Cheng C, Glover R, Mak C, et al.
Diagn Microbiol Infect Dis
. 2018 May;
91(4):331-335.
PMID: 29706478
Patients with respiratory infections are often managed presumptively until confirmation of infection status. We assessed the impact of introducing the Enigma® MiniLab™ FluAB-RSV point-of-care test (POCT) on patients admitted with...
17.
Whitlock G, Gibbons D, Longford N, Harvey M, Mcowan A, Adams E
Int J STD AIDS
. 2017 Oct;
29(5):474-482.
PMID: 29059032
Primary Outcome: time from patients' sample collection to notification of test results at DSE compared with 56DS. Secondary outcomes estimated using a model: number of transmissions prevented and the number...
18.
Turner K, Christensen H, Adams E, McAdams D, Fifer H, McDonnell A, et al.
BMJ Open
. 2017 Jun;
7(6):e015447.
PMID: 28615273
Objective: To create a mathematical model to investigate the treatment impact and economic implications of introducing an antimicrobial resistance point-of-care test (AMR POCT) for gonorrhoea as a way of extending...
19.
Bustinduy A, Jeyaratnam D, Douthwaite S, Tonkin-Crine S, Shaw R, Hyrapetian L, et al.
Acta Paediatr
. 2017 Apr;
106(7):1192-1195.
PMID: 28374509
No abstract available.
20.
Vynnycky E, Adams E, Cutts F, Reef S, Navar A, Simons E, et al.
PLoS One
. 2016 Mar;
11(3):e0149160.
PMID: 26962867
Background: The burden of Congenital Rubella Syndrome (CRS) is typically underestimated in routine surveillance. Updated estimates are needed following the recent WHO position paper on rubella and recent GAVI initiatives,...